Bone Biologics Corp financial data

Symbol
BBLG, BBLGW on Nasdaq
Location
2 Burlington Woods Drive,, Suite 100,, Burlington, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
AFH ACQUISITION X, INC. (to 9/15/2014)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 955 %
Debt-to-equity 11.7 % -78%
Return On Equity -125 % +12.8%
Return On Assets -112 % -19.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.46M shares -21.4%
Common Stock, Shares, Outstanding 2.1M shares -33.1%
Entity Public Float 4.16M USD -5.47%
Common Stock, Value, Issued 2.1K USD -33.1%
Weighted Average Number of Shares Outstanding, Basic 1.75M shares +347%
Weighted Average Number of Shares Outstanding, Diluted 1.75M shares +347%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.47M USD -79.6%
General and Administrative Expense 2.35M USD +0.54%
Operating Income (Loss) -3.82M USD +60%
Nonoperating Income (Expense) -316K USD -93.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -2.52M USD -33.6%
Income Tax Expense (Benefit) 33.1K USD
Net Income (Loss) Attributable to Parent -4.14M USD +36.4%
Earnings Per Share, Basic 28.3 USD/shares +51.6%
Earnings Per Share, Diluted 28.3 USD/shares +51.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.19M USD +6.43%
Assets, Current 4.07M USD
Assets 4.07M USD -18.3%
Liabilities, Current 273K USD -76.9%
Liabilities 273K USD -76.9%
Retained Earnings (Accumulated Deficit) -83.5M USD -5.22%
Stockholders' Equity Attributable to Parent 3.79M USD -0.02%
Liabilities and Equity 4.07M USD -18.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.3M USD +3.45%
Net Cash Provided by (Used in) Financing Activities 1.5M USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 2.1M shares -33.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 201K USD
Deferred Tax Assets, Valuation Allowance 20.4M USD +0.29%
Deferred Tax Assets, Gross 20.4M USD +0.29%
Deferred Tax Assets, Operating Loss Carryforwards 9.59M USD -12.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Additional Paid in Capital 87.3M USD +4.98%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%